SCHEMBL4702017

SCHEMBL4702017

NC(=O)N1CCCCC1=O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.52
TSHR P16473 1/20 0.44
MITF O75030 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
KMT2A Q03164 2/20 0.39
CA12 O43570 1/20 0.39
CA1 P00915 1/20 0.39
CA2 P00918 1/20 0.39
CA3 P07451 1/20 0.39
CA4 P22748 1/20 0.39
CA6 P23280 1/20 0.39
CA5A P35218 1/20 0.39
CA7 P43166 1/20 0.39
CA9 Q16790 1/20 0.39
CA13 Q8N1Q1 1/20 0.39
CA14 Q9ULX7 1/20 0.39
CA5B Q9Y2D0 1/20 0.39
KDM4E B2RXH2 3/20 0.39
MAPT P10636 2/20 0.39
MEN1 O00255 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1424272 0.98 LMNA (0.50) LMNATSHRMITFSMN1; SMN2KMT2A
Squamolone SCHEMBL1051735 0.93
Squamolone SCHEMBL28367081 0.91 LMNA (0.57) LMNATSHRMITFSMN1; SMN2KMT2A
SCHEMBL6538147 0.83
SCHEMBL7687599 0.81 LMNA (0.56) LMNATSHRMITFSMN1; SMN2KMT2A
SCHEMBL131845 0.79 LMNA (0.54) LMNATSHRMITFSMN1; SMN2KMT2A
SCHEMBL1238335 0.79 LMNA (0.54) LMNATSHRMITFSMN1; SMN2KMT2A
SCHEMBL5181091 0.79 LMNA (0.54) LMNATSHRMITFSMN1; SMN2KMT2A
SCHEMBL8379227 0.79 LMNA (0.54) LMNATSHRMITFSMN1; SMN2KMT2A
SCHEMBL4059818 0.77 LMNA (0.52) LMNATSHRMITFSMN1; SMN2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101312724-A Tetrahydro-indazolyl cannabinoid modulators JANSSEN PHARMACEUTICA NV (BE) 2008-11-26 CN claimed
EP-1931336-A1 TETRAHYDRO-INDAZOLYL CANNABINOID MODULATORS Janssen Pharmaceutica, N.V. (BE) 2008-06-18 EP claimed
US-20070117857-A1 Substituted 3-amido-tetrahydro-indazolyl cannabinoid modulators JANSSEN PHARMACEUTICA, N.V. 2007-05-24 US claimed
WO-2007038045-A1 TETRAHYDRO-INDAZOLYL CANNABINOID MODULATORS JANSSEN PHARMACEUTICA, N.V. (BE) 2007-04-05 WO claimed
EP-3917513-A1 SREBP INHIBITORS COMPRISING A THIOPHENE CENTRAL RING Capulus Therapeutics, LLC (US) 2021-12-08 EP disclosed
WO-2020159889-A1 SREBP INHIBITORS COMPRISING A THIOPHENE CENTRAL RING CAPULUS THERAPEUTICS, LLC (US) 2020-08-06 WO disclosed
CN-101312724-A Tetrahydro-indazolyl cannabinoid modulators JANSSEN PHARMACEUTICA NV (BE) 2008-11-26 CN disclosed
EP-1966194-A2 SUBSTITUTED 5-HETEROARYL-1-PHENYL-PYRAZOLE CANNABINOID MODULATORS JANSSEN PHARMACEUTICA N.V. (BE) 2008-09-10 EP disclosed
EP-1931336-A1 TETRAHYDRO-INDAZOLYL CANNABINOID MODULATORS Janssen Pharmaceutica, N.V. (BE) 2008-06-18 EP disclosed
WO-2007061948-A2 SUBSTITUTED 5-HETEROARYL-1-PHENYL-PYRAZOLE CANNABINOID MODULATORS JANSSEN PHARMACEUTICA, N.V. (BE) 2007-05-31 WO disclosed
US-20070117857-A1 Substituted 3-amido-tetrahydro-indazolyl cannabinoid modulators JANSSEN PHARMACEUTICA, N.V. 2007-05-24 US disclosed
US-20070117858-A1 SUBSTITUTED 5-HETEROARYL-1-PHENYL-PYRAZOLE CANNABINOID MODULATORS JANSSEN PHARMACEUTICA, N.V. (BE) 2007-05-24 US disclosed
WO-2007038045-A1 TETRAHYDRO-INDAZOLYL CANNABINOID MODULATORS JANSSEN PHARMACEUTICA, N.V. (BE) 2007-04-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070117857-A1 Substituted 3-amido-tetrahydro-indazolyl cannabinoid modulators CNR2, CNR1, GPR18 LMNA 3709/4885TSHR 1203/4885MITF 4133/4885
US-20070117858-A1 SUBSTITUTED 5-HETEROARYL-1-PHENYL-PYRAZOLE CANNABINOID MODULATORS CNR1, CNR2, GPR18 LMNA 4037/4885TSHR 1638/4885MITF 3505/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.